Biomarkers for Gestational Trophoblastic Disease
What is this project about?
Identification of Biomarkers for the Diagnosis, Management and Follow-up of Women with Gestational Trophoblastic Disease
Gestational Trophoblastic Disease (GTD) also known as molar pregnancy is a rare disorder affecting one in 600 pregnancies. Most molar pregnancies resolve following uterine evacuation but some progress to malignant disease requiring chemotherapy. The pregnancy hormone, human chorionic gonadotrophin (hCG) is not an ideal biomarker for GTD as it is prone to false positive/negative results.
This project aims to identify more sensitive biomarkers for GTD to allow earlier detection of disease recurrence and progression to malignant disease.
What is involved?
- National survey of women on the GTD Registry
- Systematic review on the use of hCG in diagnosis, monitoring and treatment of GTD
- Audit of molar pregnancy comparing histological and genetic classification
- Evaluation of commercial hCG immunoassays used in the diagnosis and monitoring of GTD
- Evaluation of new biomarkers for use in the diagnosis and monitoring of Gestational Trophoblastic Neoplasia (GTN) - placental growth factor (PIGF) and cell free DNA (cfDNA)
- Qualitative study of General Practitioners as stakeholders engaging with patients on the GTD Registry.
Who is involved?
|Caroline Joyce||Pregnancy Loss Research Group||PhD Student|
|Professor Keelin O'Donoghue||Pregnancy Loss Research Group||Primary Supervisor|
|Dr John Coulter||Department of Obstetrics & Gynaecology, Cork University Maternity Hospital, Cork||Co-supervisor|
|Professor Tommie McCarthy||School of Biochemistry & Cell Biology, University College Cork||Co-supervisor|
|Dr Brendan Fitzgerald||Pregnancy Loss Research Group; Department of Pathology, Cork University Hospital, Cork||Collaborator|
|Professor Michael Seckl||Trophoblastic Tumour Screening & Treatment Centre, Charing Cross Hospital, London, United Kingdom||Collaborator|
|Dr Geoffrey Maher||Trophoblastic Tumour Screening & Treatment Centre, Charing Cross Hospital, London, United Kingdom||Collaborator|
- Joyce CM, Coulter J, Kenneally C, McCarthy TV, O'Donoghue K. Experience of women on the Irish National Gestational Trophoblastic Disease Registry. European Journal of Obstetrics and Gynecology and Reproductive Biology. 2022;272:206-212. https://doi.org/10.1016/j.ejogrb.2022.03.039.
- Joyce CM, Fitzgerald B, McCarthy TV, Coulter J, O'Donoghue K. Advances in the diagnosis and early management of gestational trophoblastic disease. BMJ Medicine. 2022;1:e000321. https://doi.org/10.1136/bmjmed-2022-000321.
- Hamid M, Joyce CM, Carroll HK, Kenneally C, Mulcahy S, O'Neill M-K, Coulter J, O'Reilly S. Challenging gestational trophoblastic disease cases and mimics: An exemplar for the management of rare tumours. European Journal of Obstetrics and Gynecology and Reproductive Biology. 2023;286:76-84. https://doi.org/10.1016/j.ejogrb.2023.05.016.
- Health Service Executive (2022, May 13) Launch of the updated National Clinical Guideline – Diagnosis, staging and treatment of patients with gestational trophoblastic disease (GTD) 2022, https://www.hse.ie/eng/services/news/media/pressrel/launch-of-the-updated-national-clinical-guideline-diagnosis-staging-and-treatment-of-patients-with-gestational-trophoblastic-disease-gtd-2022.html.
Ongoing: July 2019 to September 2023
Please email Caroline Joyce: firstname.lastname@example.org